EVGN · Evogene Ltd Ordinary Shares
View on chartInsiders & Stakes
| Leon Recanati Director | ▲ Buy | Open Market | 1,343,886 Shares held | 8/11/2026 | View profile |
| Tarcic Gabi Chief Development Officer | ▲ Buy | Open Market | 1,129 Shares held | 6/4/2026 | View profile |
Transaction History
| Leon Recanati | ▲ Buy | Open Market | 460,000 | $292K | 8/11/2026 |
| Leon Recanati | ▲ Buy | Open Market | 800,000 | $400K | 8/4/2026 |
| Tarcic Gabi | ▲ Buy | Open Market | 1,129 | $677 | 6/4/2026 |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 2, 2026
Evogene gets 180-day extension for Nasdaq bid price compliance
Evogene announced that Nasdaq granted an additional 180-day period to regain compliance with the minimum bid price requirement. This extension allows the company until March 29, 2027, to meet the exchange's listing standards. The news highlights ongoing challenges for the stock, which has traded as low as $0.35 over the past year.
Evogene gets 180-day extension for Nasdaq bid price compliance. Evogene announced that Nasdaq granted an additional 180-day period to regain compliance with the minimum bid price requirement. This extension allows the company until March 29, 2027, to meet the exchange's listing standards. The news highlights ongoing challenges for the stock, which has traded as low as $0.35 over the past year.